Literature DB >> 20849795

Multimodality treatment of intracranial dural arteriovenous fistulas in the Onyx era: a single center experience.

Sabareesh K Natarajan1, Basavaraj Ghodke, Louis J Kim, Danial K Hallam, Gavin W Britz, Laligam N Sekhar.   

Abstract

BACKGROUND: The results of treatment of intracranial dural arteriovenous fistulas (DAVFs) since Onyx became available as an embolic agent at our institution is reported. An algorithm is presented for treatment of DAVFs with Onyx, and the role of endovascular transvenous, surgical, and radiosurgical approaches are presented.
METHODS: Thirty-two patients with DAVFs treated between November 2005 and November 2008 by endovascular embolization, surgery, or radiosurgery were identified by a retrospective chart review. Treatment strategies were based on the location or complexity of the fistula and the patient's clinical status. Data collected included DAVF characteristics, obliteration rates, complications, and outcomes. The results were analyzed and correlated with the treatment modality.
RESULTS: Presenting symptoms were as follows: hemorrhage (n = 12 patients), headaches (n = 12), tinnitus (n = 5), orbital symptoms (n = 7), and seizures (n = 1). Thirty patients were treated by endovascular embolization (transarterial only with Onyx-21, transvenous only with platinum coils-6, transarterial [Onyx] and transvenous [coils]-3). Five patients (4 after incomplete/failed embolization) had surgical excision of the fistula. Three patients were treated with Gamma Knife radiosurgery (primary-1, 2 after incomplete/failed embolization). The locations of the fistulas were transverse sigmoid (10 patients), petrotentorial (7 patients), indirect carotid cavernous fistula (7 patients), parasagittal/falcine (3 patients), middle fossa dura (3 patients), torcula (1 patient), and anterior fossa dura (1 patient). The distribution of patients according to Borden classification was I-6, II-13, and III-13. Complete obliteration of the fistula was achieved in 26/32 (81%) patients after multimodal treatment. All surgical cases had complete obliteration. In the high-risk group with cortical venous reflux, 23/26 (89%) patients were cured. Endovascular complications included a stuck microcatheter tip with fracture of the tip in two patients and cranial nerves V and VII palsies in one patient. At last follow-up (range 1-36 months), 24 patients had modified Rankin score of 0-2, 5 patients had modified Rankin score of 3-5, and 3 patients were dead. Two patients died during admission due to the insult of the hemorrhage, and one died after an accidental fall with subsequent traumatic subdural hematoma.
CONCLUSIONS: Multimodality treatment of DAVFs has high success rates for cure at our center. Transarterial embolization with Onyx has become the primary treatment for intracranial DAVFs at our center and is associated with high safety profile and efficacy. Transvenous coil embolization is still preferred in DAVFs with supply from arterial branches supplying cranial nerves, predominant internal carotid artery feeders and potential extracranial-intracranial collateral anastomosis. In our series, patients with incompletely treated DAVFs were treated with surgery and those with partially treated type I fistulas had radiosurgery for palliation.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20849795     DOI: 10.1016/j.wneu.2010.01.009

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  28 in total

1.  Changing Clinical and Therapeutic Trends in Tentorial Dural Arteriovenous Fistulas: A Systematic Review.

Authors:  D Cannizzaro; W Brinjikji; S Rammos; M H Murad; G Lanzino
Journal:  AJNR Am J Neuroradiol       Date:  2015-08-27       Impact factor: 3.825

2.  Onyx Embolization of Dural Arteriovenous Fistula, using Scepter C Balloon Catheter: a Case Report.

Authors:  Sung Tae Kim; Hae Woong Jeong; Jeonghwa Seo
Journal:  Neurointervention       Date:  2013-08-29

3.  Recurrence of "cured" dural arteriovenous fistulas after Onyx embolization.

Authors:  Peter Adamczyk; Arun Paul Amar; William J Mack; Donald W Larsen
Journal:  Neurosurg Focus       Date:  2012-05       Impact factor: 4.047

4.  Fluoroscopy-Assisted Transnasal Onyx Occlusion of the Eustachian Tube for Lateral Skull Base Cerebrospinal Fluid Leak Repair.

Authors:  Neil S Patel; Matthew L Carlson
Journal:  J Neurol Surg B Skull Base       Date:  2018-02-14

5.  Hybrid surgery for dural arteriovenous fistula in the neurosurgical hybrid operating suite.

Authors:  Shih-Chieh Shen; Yuang-Seng Tsuei; Wen-Hsien Chen; Chiung-Chyi Shen
Journal:  BMJ Case Rep       Date:  2014-01-23

6.  Use of ethylene-vinyl alcohol copolymer as a liquid embolic agent to treat a peripheral arteriovenous malformation in a dog.

Authors:  William T N Culp; Craig B Glaiberman; Rachel E Pollard; Erik R Wisner
Journal:  J Am Vet Med Assoc       Date:  2014-07-15       Impact factor: 1.936

7.  Spontaneous Aggressive Conversion of Venous Drainage Pattern in Dural Arteriovenous Fistula Treated with Onyx Embolization.

Authors:  Yeongu Chung; Seok Keun Choi; Sung Ho Lee; Eui Jong Kim
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2016-12-31

8.  Safety of Onyx Transarterial Embolization of Skull Base Dural Arteriovenous Fistulas from Meningeal Branches of the External Carotids also Fed by Meningeal Branches of Internal Carotid or Vertebral Arteries.

Authors:  Thiago G Abud; Emmanuel Houdart; Jean-Pierre Saint-Maurice; Daniel G Abud; Carlos E Baccin; Andrew D Nguyen; Nitamar Abdala
Journal:  Clin Neuroradiol       Date:  2017-08-11       Impact factor: 3.649

9.  Endovascular management of six simultaneous intracranial dural arteriovenous fistulas in a single patient.

Authors:  Taylor L Gist; Leonardo Rangel-Castilla; Chandan Krishna; Gustavo C Roman; David A Cech; Orlando Diaz
Journal:  BMJ Case Rep       Date:  2013-03-07

10.  Onyx versus nBCA and coils in the treatment of intracranial dural arteriovenous fistulas.

Authors:  Douglas M Choo; Jai Jai Shiva Shankar
Journal:  Interv Neuroradiol       Date:  2016-01-08       Impact factor: 1.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.